Diagnostic significance of serum concentrations of soluble Fas ligand (sFasL) in children with autoimmune thyroid disease

References

• Antonelli, A., S. M. Ferrari, A. Corrado, et al. 2015. Autoimmune thyroid disorders. Autoimmun Rev. 14: 174–180
   PubMed Web of Science ®Google Scholar
• Mikos, H., M. Mikos, M. Obara-Moszynska, and M. Niedziela. 2014. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 65: 150–155
   PubMed Web of Science ®Google Scholar
• Mikos, H., M. Mikos, B. Rabska-Pietrzak, and M. Niedziela. 2014. The clinical role of serum concentrations of selected cytokines: IL-1beta, TNF-alpha and IL-6 in diagnosis of autoimmune thyroid disease (AITD) in children. Autoimmunity. 47: 466–472
   PubMed Web of Science ®Google Scholar
• Schneider, P., J. L. Bodmer, N. Holler, et al. 1997. Characterization of Fas (Apo-1, CD95)-Fas ligand interaction. J Biol. Chem 272: 18827–18833
   PubMed Web of Science ®Google Scholar
• Mitsiades, N., V. Poulaki, G. Mastorakos, et al. 1999. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J. Clin. Endocrinol. Metab. 84: 2924–2932
   PubMed Web of Science ®Google Scholar
• Bossowski, A., B. Czarnocka, K. Bardadin, et al. 2008. Identification of apoptotic proteins in thyroid gland from patients with Graves' disease and Hashimoto's thyroiditis. Autoimmunity. 41: 163–173
   PubMed Web of Science ®Google Scholar
• Stassi, G., and R. De Maria. 2002. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat. Rev. Immunol. 2: 195–204
   PubMed Web of Science ®Google Scholar
• Parlato, S., A. M. Giammarioli, M. Logozzi, et al. 2000. CD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathway. Embo J. 19: 5123–5134
   PubMed Web of Science ®Google Scholar
• Mezosi, E., S. H. Wang, S. Utsugi, et al. 2005. Induction and regulation of Fas-mediated apoptosis in human thyroid epithelial cells. Mol. Endocrinol. 19: 804–811
   PubMed Web of Science ®Google Scholar
• Krammer, P. H. 2000. CD95's deadly mission in the immune system. Nature. 407: 789–795
   PubMed Web of Science ®Google Scholar
• de Jong, S., T. Timmer, F. J. Heijenbrok, and E. G. de Vries. 2001. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev. 20: 51–56
   PubMed Web of Science ®Google Scholar
• Kayagaki, N., A. Kawasaki, T. Ebata, et al. 1995. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182: 1777–1783
   PubMed Web of Science ®Google Scholar
• Askenasy, N., E. S. Yolcu, I. Yaniv, and H. Shirwan. 2005. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood. 105: 1396–1404
   PubMed Web of Science ®Google Scholar
• Kim, S., J. Y. Ki, T. H. Lee, et al. 2002. Soluble Fas ligand-susceptible "memory" cells in mice but not in human: potential role of soluble Fas ligand in deletion of auto-reactive cells. Autoimmunity. 35: 15–20
   PubMed Web of Science ®Google Scholar
• Linkermann, A., J. Qian, M. Lettau, et al. 2005. Considering Fas ligand as a target for therapy. Expert. Opin. Ther. Targets. 9: 119–134
   PubMed Web of Science ®Google Scholar
• Palczewska, I., and Z. Niedzwiedzka. 2001. [Somatic development indices in children and youth of Warsaw]. Medycyna. Wieku. Rozwojowego. 5: 18–118
   PubMedGoogle Scholar
• Mitsiades, N., V. Poulaki, C. S. Mitsiades, et al. 2001. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends. Endocrinol. Metab. 12: 384–390
   PubMed Web of Science ®Google Scholar
• Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267: 1449–1456
   PubMed Web of Science ®Google Scholar
• Wang, S. H., J. D. Bretz, E. Phelps, et al. 2002. A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J. Immunol. 168: 2470–2474
   PubMed Web of Science ®Google Scholar
• Kawakami, A., K. Eguchi, N. Matsuoka, et al. 1996. Thyroid-stimulating hormone inhibits Fas antigen-mediated apoptosis of human thyrocytes in vitro. Endocrinology. 137: 3163–3169
   PubMed Web of Science ®Google Scholar
• Giordano, C., G. Stassi, R. De Maria, et al. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275: 960–963
   PubMed Web of Science ®Google Scholar
• Fountoulakis, S., G. Vartholomatos, N. Kolaitis, et al. 2008. HLA-DR expressing peripheral T regulatory cells in newly diagnosed patients with different forms of autoimmune thyroid disease. Thyroid. 18: 1195–1200
   PubMed Web of Science ®Google Scholar
• Wang, S. H., M. Van Antwerp, R. Kuick, et al. 2007. Microarray analysis of cytokine activation of apoptosis pathways in the thyroid. Endocrinology. 148: 4844–4852
   PubMed Web of Science ®Google Scholar
• Kaczmarek, E., K. Lacka, D. Jarmolowska-Jurczyszyn, et al. 2011. Changes of B and T lymphocytes and selected apopotosis markers in Hashimoto's thyroiditis. J. Clin. Pathol. 64: 626–630
   PubMed Web of Science ®Google Scholar
• Fountoulakis, S., G. Vartholomatos, N. Kolaitis, et al. 2008. Differential expression of Fas system apoptotic molecules in peripheral lymphocytes from patients with Graves' disease and Hashimoto's thyroiditis. Eur. J. Endocrinol. 158: 853–859
   PubMed Web of Science ®Google Scholar
• Bossowski, A., B. Czarnocka, A. Stasiak-Barmuta, et al. 2007. [Analysis of Fas, FasL and Caspase-8 expression in thyroid gland in young patients with immune and non-immune thyroid diseases]. Endokrynol. Pol. 58: 303–313
   PubMedGoogle Scholar
• Andrikoula, M., and A. Tsatsoulis. 2001. The role of Fas-mediated apoptosis in thyroid disease. Eur. J. Endocrinol. 144: 561–568
   PubMed Web of Science ®Google Scholar
• Giordano, C., P. Richiusa, M. Bagnasco, et al. 2001. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlates with opposite phenotypic manifestations of autoimmune thyroid disease. Thyroid. 11: 233–244
   PubMed Web of Science ®Google Scholar
• Salmaso, C., M. Bagnasco, G. Pesce, et al. 2002. Regulation of apoptosis in endocrine autoimmunity: insights from Hashimoto's thyroiditis and Graves' disease. Ann. N Y Acad. Sci. 966: 496–501
   PubMed Web of Science ®Google Scholar
• Stassi, G., A. Zeuner, D. Di Liberto, et al. 2001. Fas-FasL in Hashimoto's thyroiditis. J. Clin. Immunol. 21: 19–23
   PubMed Web of Science ®Google Scholar
• Chen, S., S. M. Fazle Akbar, Z. Zhen, et al. 2004. Analysis of the expression of Fas, FasL and Bcl-2 in the pathogenesis of autoimmune thyroid disorders. Cell. Mol. Immunol. 1: 224–228
   PubMed Web of Science ®Google Scholar
• Xu, W. C., S. R. Chen, J. X. Huang, et al. 2007. Expression and distribution of S-100 protein, CD83 and apoptosis-related proteins (Fas, FasL and Bcl-2) in thyroid tissues of autoimmune thyroid diseases. Eur. J. Histochem. 51: 291–300
   PubMed Web of Science ®Google Scholar
• Wang, S. H., and J. R. Baker. 2007. The role of apoptosis in thyroid autoimmunity. Thyroid. 17: 975–979
   PubMed Web of Science ®Google Scholar
• Wang, C. Y., W. B. Zhong, T. C. Chang, and Y. F. Tsai. 2002. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism. Metabolism. 51: 769–773
   PubMed Web of Science ®Google Scholar
• Andrikoula, M., N. Kolaitis, G. Vartholomatos, and A. Tsatsoulis. 2009. Serum levels of soluble fas in patients with multinodular goiter. Immunol. Invest. 38: 398–407
   PubMed Web of Science ®Google Scholar
• Hiromatsu, Y., T. Bednarczuk, E. Soyejima, et al. 1999. Increased serum soluble Fas in patients with Graves' disease. Thyroid. 9: 341–345
   PubMed Web of Science ®Google Scholar
• Feldkamp, J., E. Pascher, M. Schott, et al. 2001. Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease. J. Clin. Endocrinol. Metab. 86: 4250–4253
   PubMed Web of Science ®Google Scholar
• Ohtsuka, K., and M. Hashimoto. 2000. Serum levels of soluble Fas in patients with Graves' ophthalmopathy. Br. J. Ophthalmol. 84: 103–106
   PubMed Web of Science ®Google Scholar
• Mysliwiec, J., A. Kretowski, A. Stepien, M. et al. 2004. [Serum Fas in patients with Graves' ophthalmopathy as a marker of activity of the ocular inflammatory infiltration]. Pol. Merkur. Lekarski. 17: 368–370
   PubMedGoogle Scholar
• Maeda, K., Y. Ohara, M. Hashimoto, and H. Ohguro. 2008. Analysis of sFas IL-6 levels in thyroid-associated ophthalmopathy: pre- or poststeroid pulse treatment. Clin. Ophthalmol. 2: 609–612
   PubMedGoogle Scholar
• Takeda, K., E. Ohara, T. Kaneda, et al. 1999. [Increased serum soluble Fas ligand in hyperthyroid Graves' disease]. Rinsho. Byori. 47: 961–965
   PubMedGoogle Scholar
• Kolomecki, K., P. Maciaszczyk, H. Stepien, et al. 2005. P53 concentration and soluble FasL (sFasL) serum level as indicators of apoptosis in patients with benign and malignant thyroid tumors. Bratisl. Lek. Listy. 106: 297–300
   PubMedGoogle Scholar
• Mysliwiec, J., M. Okota, A. Nikolajuk, and M. Gorska. 2006. Soluble Fas, Fas ligand and Bcl-2 in autoimmune thyroid diseases: relation to humoral immune response markers. Adv. Med. Sci. 51: 119–122
   PubMedGoogle Scholar
• Kandror, V. I., I. V. Babkina, S. I. Krainova, et al. 2004. Increase in serum concentration of FAS ligand as a possible mechanism for antithyroid cytotoxicity during autoimmune thyroid diseases. Bull. Exp. Biol. Med. 138: 37–39
   PubMed Web of Science ®Google Scholar